Developing biomarker-guided treatments for lung cancer

Luis Raez, MD, Memorial Cancer Institute, Pembroke Pines, FL, comments on updates on targeted therapies for lung cancer. Whilst some frequently seen mutations such as KRAS G12C have several treatment options, patients with p53 mutations do not have any available therapies. Lung cancer with STK11 and KEAP1 alterations additionally have promising immunotherapy-based strategies based on findings from the CheckMate 9LA (NCT03215706) and POSEIDON (NCT03164616) trials. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.